TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
Neuronetics (NASDAQ: STIM) announced that TriWest, the TRICARE regional administrator, updated its medical policy effective Nov 12, 2025 to cover NeuroStar TMS for adolescents aged 15 and older. The change applies immediately to TRICARE beneficiaries in 26 states, expanding access to a non‑drug, FDA‑cleared adolescent TMS option.
The release notes NeuroStar received FDA clearance for adolescents in 2024, cites an estimated 4.3 million U.S. adolescents aged 15–21 affected by major depression, and lists several private insurers that already cover NeuroStar.
Neuronetics (NASDAQ: STIM) ha annunciato che TriWest, l'amministratore regionale TRICARE, ha aggiornato la sua policy medica a partire dal 12 novembre 2025 per includere NeuroStar TMS per adolescenti di 15 anni e oltre. La modifica si applica immediatamente ai beneficiari TRICARE in 26 stati, ampliando l'accesso a una opzione TMS per adolescenti non farmacologica e approvata dalla FDA.
Il comunicato riferisce che NeuroStar ha ricevuto l'approvazione FDA per adolescenti nel 2024, cita una stima di 4,3 milioni di adolescenti statunitensi di età compresa tra 15 e 21 colpiti dalla depressione maggiore e elenca diverse assicurazioni private che già coprono NeuroStar.
Neuronetics (NASDAQ: STIM) anunció que TriWest, el administrador regional de TRICARE, actualizó su política médica a partir del 12 de noviembre de 2025 para cubrir NeuroStar TMS para adolescentes de 15 años en adelante. El cambio se aplica de inmediato a los beneficiarios de TRICARE en 26 estados, ampliando el acceso a una opción TMS para adolescentes no farmacológica y aprobada por la FDA.
El comunicado señala que NeuroStar recibió la aprobación de la FDA para adolescentes en 2024, cita una estimación de 4,3 millones de adolescentes estadounidenses de 15 a 21 años afectados por la depresión mayor, y enumera varios aseguradores privados que ya cubren NeuroStar.
Neuronetics (나스닥: STIM)은 TriWest가 TRICARE 지역 관리자로서 2025년 11월 12일부터 청소년 15세 이상을 위한 NeuroStar TMS를 커버하도록 의료 정책을 업데이트했다고 발표했습니다. 이 변경은 26개 주의 TRICARE 수혜자들에게 즉시 적용되며 약물 없이 FDA 승인된 청소년용 TMS 옵션에 대한 접근을 확대합니다.
발표 자료에 따르면 NeuroStar는 2024년 청소년에 대한 FDA 승인을 받았다고 하며, 15~21세의 미국 청소년 중 주요 우울증에 영향을 받는 것으로 추정되는 430만 명에 이르고, NeuroStar를 이미 커버하는 여러 민간 보험사를 나열합니다.
Neuronetics (NASDAQ: STIM) a annoncé que TriWest, l'administrateur régional TRICARE, a mis à jour sa politique médicale à compter du 12 novembre 2025 pour couvrir NeuroStar TMS pour les adolescents de 15 ans et plus. Le changement s'applique immédiatement aux bénéficiaires TRICARE dans 26 États, élargissant l'accès à une option TMS non médicamenteuse et approuvée par la FDA pour les adolescents.
Le communiqué indique que NeuroStar a obtenu l'approbation de la FDA pour les adolescents en 2024, cite une estimation de 4,3 millions d'adolescents américains âgés de 15 à 21 ans touchés par la dépression majeure, et liste plusieurs assureurs privés qui couvrent déjà NeuroStar.
Neuronetics (NASDAQ: STIM) kündigte an, dass TriWest, der TRICARE-Regionalverwalter, seine medizinische Richtlinie mit Wirkung vom 12. November 2025 aktualisiert hat, um NeuroStar TMS für Jugendliche ab 15 Jahren abzudecken. Die Änderung gilt sofort für TRICARE-Berechtigte in 26 Bundesstaaten und erweitert den Zugang zu einer nicht medikamentösen, von der FDA freigegebenen TMS-Option für Jugendliche.
Die Mitteilung erwähnt, dass NeuroStar im Jahr 2024 eine FDA-Zulassung für Jugendliche erhielt, nennt eine geschätzte Zahl von 4,3 Millionen US-amerikanischen Jugendlichen im Alter von 15 bis 21 Jahren, die von schweren Depressionen betroffen sind, und listet mehrere private Versicherer auf, die NeuroStar bereits abdecken.
Neuronetics (المدرجة في ناسداك: STIM) أعلنت أن TriWest، المُدير الإقليمي لـ TRICARE، حدّث سياسته الطبية اعتباراً من 12 نوفمبر 2025 لتشمل NeuroStar TMS للمراهقين بعمر 15 عاماً فأكثر. ينطبق التغيير فوراً على المستفيدين من TRICARE في 26 ولاية، مما يوسع الوصول إلى خيار TMS للمراهقين غير الدوائي ومرخص من FDA.
تشير البيانات الصحفية إلى أن NeuroStar حصلت على ترخيص FDA للمراهقين في 2024، وتذكر تقديراً لـ 4.3 مليون مراهق أمريكي تتراوح أعمارهم بين 15 و21 عاماً مصابين بالاكتئاب الكبير، وتدرج عدة شركات تأمين خاصة تغطي NeuroStar بالفعل.
- TRICARE coverage expanded to adolescents 15+ effective Nov 12, 2025
- Applies in 26 states for TRICARE beneficiaries
- FDA clearance for adolescent NeuroStar in 2024
- Already covered by multiple major insurers named
- Coverage applies only to TRICARE beneficiaries, not nationwide civilians
- Policy covers adolescents aged 15+, excluding younger teens
- Expansion limited to beneficiaries in 26 states, not all states
Insights
TRICARE/TriWest now covers NeuroStar TMS for beneficiaries aged 15+, expanding access across 26 states effective
Neuronetics gains immediate payer access to a defined military beneficiary population, reducing a key commercial barrier to adolescent treatment uptake. The update makes NeuroStar available as a first-line and add-on non-drug option for adolescents 15+, and explicitly lists coverage across 26 states, which aligns with the company’s prior
Implementation and volume will depend on provider adoption, referral patterns within military health networks, and claims workflow with TriWest; coverage scope is limited to TRICARE beneficiaries in the listed states and therefore does not by itself expand civilian market access. Important risks include administrative hurdles in prior authorization, provider training capacity, and the time needed for clinicians to change practice for adolescents despite coverage availability.
Watch for measurable signals over the next 6–12 months: changes in claim submission volumes from TriWest, published utilization or access notices from TRICARE, and any provider-network rollouts or training programs that enable adolescent referrals. These concrete items will indicate whether coverage translates into greater treatment uptake among the specified beneficiary population.
New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 States
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical policy to include TMS coverage for adolescents aged 15 and older.
TRICARE coverage is primarily used by active and retired military service members and their eligible family members. This policy update, effective immediately, applies to TRICARE beneficiaries in the following states: Alaska, Arizona, Arkansas, California, Colorado, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Minnesota, Missouri, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington, Wisconsin, and Wyoming.
“TRICARE’s decision to expand coverage for TMS to adolescents is a significant step forward in ensuring that younger patients struggling with depression now have access to this life-changing treatment,” said Keith J. Sullivan, President and CEO of Neuronetics, Inc. “We applaud TRICARE and TriWest for recognizing the importance of providing innovative, evidence-based care to those who need it most, and we remain committed to working with providers and policymakers to expand adolescent access to TMS nationwide.”
"The demands of military life can create unique stressors for the children of service members, increasing their vulnerability to depression and other mental health challenges,” said Geoffrey Grammer, MD, Chief Medical Officer of Neuronetics and retired U.S. Army Colonel. “By expanding coverage to include NeuroStar TMS, TriWest is taking a meaningful step toward ensuring that the sons and daughters of our active-duty and retired military heroes receive the care and support that honors their families’ service to our nation."
An estimated 4.3 million U.S. adolescents aged 15-21 are affected by major depression.1 Depression amongst adolescents can disrupt crucial aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being. With limited approved medication options for adolescents with MDD, NeuroStar is a safe and effective option that can be used as a first-line, add-on treatment with remarkable clinical outcomes. As a first-line treatment, NeuroStar can be used without prior medication failures in this age group. Since receiving FDA clearance for adolescent patients in 2024, NeuroStar TMS therapy is also now covered by several leading insurers, including but not limited to: Evernorth Health Services (a Cigna company), BlueCross BlueShield Health Care Service Corporation (BCBS-HCSC), Humana, Aetna, Medi-Cal, Pacific Source, and more.
In addition to being the first TMS company with FDA clearance for adolescent treatment, Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.
For more information about NeuroStar TMS Therapy, please visit NeuroStar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.9 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.2 Greenbrook has provided more than 2 million treatments to over 60,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
References
1 World Health Organization, Depression Fact Sheet. Accessed April 29, 2024. https://www.who.int/news-room/fact-sheets/detail/depression.
2 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
FAQ
What did Neuronetics (STIM) announce on November 12, 2025 about TRICARE coverage?
Which states does TRICARE NeuroStar coverage for adolescents (STIM) apply to?
Does NeuroStar TMS have FDA clearance for adolescent use relevant to STIM investors?
Will TRICARE coverage of NeuroStar (STIM) be available immediately to military families?
How many U.S. adolescents does the announcement cite as affected by major depression?
